-
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
Source: Nasdaq GlobeNewswire / 06 Aug 2024 16:05:01 America/New_York
ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced its financial results for the second quarter ended June 30, 2024, and updates its 2024 guidance.
Second Quarter and Recent Highlights
- Total revenue of $10.4 million in the second quarter of 2024, an increase of 15% over the second quarter of 2023.
- Core business revenue of $7.6 million in the second quarter of 2024, a decline of 9% over the second quarter of 2023.
- Strategic Platform License (SPL) Program-related revenue was $2.9 million for the second quarter of 2024, an increase of 279% over the second quarter of 2023.
- Five new SPL clients signed year-to-date. Legend Biotech signed in May, Be Biopharma signed in March, and Wugen, Imugene, and Lion TCR signed in January. The total number of SPL partners now stands at 28.
- Total cash, cash equivalents and investments were $199.8 million as of June 30, 2024.
“We are pleased by our second quarter results and our business performance in the first half of 2024 and remain confident we will deliver our full year guidance. We continue to drive commercial execution in cell therapy and believe that we remain the premier cell engineering platform in the industry,” said Maher Masoud, President and CEO at MaxCyte.
“Since the beginning of the year, MaxCyte has signed five new SPLs, which includes recently signed Legend Biotech, along with Be Biopharma, in March 2024. Our total number of SPLs now stands at 28, highlighting the demand for our platform and our continued expansion into a range of different indications. As our clients continue to progress through the clinic, we believe we continue to provide the best electroporation platform with the best support for their programs. We remain excited by continued demand for our platform and our role in enabling a growing set of next-generation cell therapies.”
The following table provides details regarding the sources of our revenue for the periods presented.
Three Months Ended Six Months Ended June 30, June 30, 2024 2023 % 2024 2023 % (in thousands, except percentages) Cell therapy $ 6,218 $ 6,637 (6%) $ 12,633 $ 12,611 0% Drug discovery 1,357 1,652 (18%) 3,129 3,450 (9%) Program-related 2,854 754 279% 6,008 1,558 286% Total revenue $ 10,429 $ 9,043 15% $ 21,770 $ 17,619 24% Three Months Ended Six Months Ended June 30, June 30, 2024 2023 % 2024 2023 % (in thousands, except percentages) Instrument $ 1,762 $ 2,126 (17%) $ 3,690 $ 4,315 (14%) PAs 2,974 3,293 (10%) 6,406 5,893 9% Lease 2,610 2,667 (2%) 5,214 5,476 (5%) Other 229 203 13% 452 377 20% Total Core Revenue $ 7,575 $ 8,289 (9%) $ 15,762 $ 16,061 (2%) In addition to revenue, management regularly reviews key business metrics to evaluate our business, measure performance, identify trends affecting our business, formulate financial projections and make strategic decisions. As of the dates presented, these key metrics were as follows:
As of June 30, 2024 2023 Installed base of instruments (sold or leased) 723 654 Three Months Ended June 30, 2024 2023 Core Revenue Generated by SPL Clients as % of Core Revenue 51 % 49 % Second Quarter 2024 Financial Results
Total revenue for the second quarter of 2024 was $10.4 million, compared to $9.0 million in the second quarter of 2023, representing growth of 15%.
Core business revenue (sales and leases of instrument and disposables to cell therapy and drug discovery customers, excluding SPL Program-related revenue) for the second quarter of 2024 was $7.6 million, compared to $8.3 million in the second quarter of 2023, representing a decline of 9%.
Cell therapy revenue for the second quarter of 2024 was $6.2 million, compared to $6.6 million in the second quarter of 2023, representing a decline of 6%. Drug discovery revenue for the second quarter of 2024 was $1.4 million, compared to $1.7 million in the second quarter of 2023, representing a decline of 18%.
SPL Program-related revenue was $2.9 million in the second quarter of 2024, as compared to $0.8 million in the second quarter of 2023, representing an increase of 279% over the second quarter of 2023.
Gross profit for the second quarter of 2024 was $8.9 million (86% gross margin), compared to $7.7 million (85% gross margin) in the second quarter of 2023.
Operating expenses for the second quarter of 2024 were $20.9 million, compared to operating expenses of $20.7 million in the second quarter of 2023.
Second quarter 2024 net loss was $9.4 million compared to net loss of $10.5 million for the same period in 2023. EBITDA, a non-GAAP measure, was a loss of $10.9 million for the second quarter of 2024, compared to a loss of $12.0 million for the second quarter of 2023; stock-based compensation expense was $3.6 million in the second quarter of 2024 compared to $3.5 million in the second quarter of 2023.
First Half 2024 Financial Results
Total revenue for the first half of 2024 was $21.8 million, compared to $17.6 million in the first half of 2023, representing growth of 24%.
Core business revenue (sales and leases of instrument and disposables to cell therapy and drug discovery customers but excluding SPL Program-related revenue) for the first half of 2024 was $15.8 million, compared to $16.1 million in the first half of 2023, representing a decline of 2%.
Cell therapy revenue for the first half of 2024 was $12.6 million, compared to $12.6 million in the first half of 2023, representing flat growth. Drug discovery revenue for the first half was $3.1 million, compared to $3.5 million in the first half of 2023, representing a decline of 9%.
SPL Program-related revenue was $6.0 million in the first half of 2024, as compared to $1.6 million in program-related revenue in the first half of 2023.
Gross profit for the first half of 2024 was $18.9 million (87% gross margin), compared to $15.2 million (87% gross margin) in the same period of the prior year.
Operating expenses for the first half of 2024 were $43.1 million, compared to operating expenses of $41.5 million in the first half of 2023.
First half 2024 net loss was $18.9 million compared to net loss of $21.4 million for the same period in 2023. EBITDA, a non-GAAP measure, was a loss of $22.1 million for the first half of 2024, compared to a loss of $24.3 million for the first half of 2023; stock-based compensation expense was $6.6 million for the first half of 2024 compared to $6.8 million for the first half of 2023.
2024 Revenue Guidance
MaxCyte affirms 2024 revenue guidance for core business revenue and increases SPL Program-related revenue guidance.
MaxCyte continues to expect full year 2024 core business revenue to be flat to 5% growth compared to 2023. SPL Program-related revenue is now expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVYTM.
MaxCyte now expects to end 2024 with at least $180 million in total cash, cash equivalents and investments, up from an expected $175 million.
Webcast and Conference Call Details
MaxCyte will host a conference call today, August 6, 2024, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.
Non-GAAP Financial Measures
This press release contains EBITDA, which is a non-GAAP measure defined as earnings before interest income and expense, taxes, depreciation and amortization. MaxCyte believes that EBITDA provides useful information to management and investors relating to its results of operations. The company’s management uses this non-GAAP measure to compare the company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The company believes that the use of EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.
Management does not consider EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of EBITDA is that it excludes significant expenses that are required by GAAP to be recorded in the company’s financial statements. In order to compensate for these limitations, management presents EBITDA together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of net loss, the most comparable GAAP financial measure, to EBITDA is included at the end of this release. MaxCyte urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company’s business.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements about us and our industry involve substantial known and unknown risks, uncertainties, and assumptions that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements include, but are not limited to, statements about the Company’s projected full-year total revenue, core revenue, and SPL program revenue and statements about possible or future results of operations or financial position. In some cases, you can identify forward-looking statements because they contain words such as "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," “contemplate,” "target,” the negative of these words and similar words or expressions. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. The forward-looking statements contained in this press release, include, without limitation, statements concerning the following: our expected future growth and success of our business model; the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share, and achieve and maintain industry leadership; our ability to expand our customer base and enter into additional SPL partnerships; our expectation that our partners will have access to capital markets to develop and commercialize their cell therapy programs; our financial performance and capital requirements; and the amount and adequacy of our cash resources.
These and other risks and uncertainties are described in greater detail in Item 1A , entitled "Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on or about March 12, 2024, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.comUS Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
venes@spectrumscience.comNominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.comMaxCyte, Inc.
Unaudited Consolidated Balance Sheets
(in thousands, except share and per share amounts)June 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 37,513 $ 46,506 Short-term investments, at amortized cost 119,817 121,782 Accounts receivable, net 4,581 5,778 Inventory 11,159 12,229 Prepaid expenses and other current assets 2,577 3,899 Total current assets 175,647 190,194 Investments, non-current, at amortized cost 42,481 42,938 Property and equipment, net 21,720 23,513 Right-of-use asset - operating leases 11,008 11,241 Other assets 640 388 Total assets $ 251,496 $ 268,274 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 953 $ 743 Accrued expenses and other 7,076 11,269 Operating lease liability, current 878 774 Deferred revenue, current portion 3,368 5,069 Total current liabilities 12,275 17,855 Operating lease liability, net of current portion 17,650 17,969 Other liabilities 310 283 Total liabilities 30,235 36,107 Commitments and contingencies Stockholders’ equity Preferred stock, $0.01 par value; 5,000,000 shares authorized and no shares issued and outstanding at June 30, 2024 and December 31, 2023 — — Common stock, $0.01 par value; 400,000,000 shares authorized, 104,824,124 and 103,961,670 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 1,048 1,040 Additional paid-in capital 414,912 406,925 Accumulated deficit (194,699 ) (175,798 ) Total stockholders’ equity 221,261 232,167 Total liabilities and stockholders’ equity $ 251,496 $ 268,274 MaxCyte, Inc.
Unaudited Consolidated Statements of Operations
(in thousands, except share and per share amounts)Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Revenue $ 10,429 $ 9,043 $ 21,770 $ 17,619 Cost of goods sold 1,488 1,376 2,891 2,376 Gross profit 8,941 7,667 18,879 15,243 Operating expenses: Research and development 5,619 5,664 12,297 11,711 Sales and marketing 6,617 6,436 13,981 12,732 General and administrative 7,639 7,663 14,742 15,161 Depreciation and amortization 1,034 977 2,102 1,890 Total operating expenses 20,909 20,740 43,122 41,494 Operating loss (11,968 ) (13,073 ) (24,243 ) (26,251 ) Other income: Interest income 2,593 2,561 5,342 4,857 Total other income 2,593 2,561 5,342 4,857 Net loss $ (9,375 ) $ (10,512 ) $ (18,901 ) $ (21,394 ) Basic and diluted net loss per share $ (0.09 ) $ (0.10 ) $ (0.18 ) $ (0.21 ) Weighted average shares outstanding,
basic and diluted104,639,239 103,063,606 104,364,498 102,955,422 MaxCyte, Inc.
Unaudited Consolidated Statements of Cash Flows
(in thousands)Six Months ended June 30, 2024 2023 Cash flows from operating activities: Net loss $ (18,901 ) $ (21,394 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 2,192 1,988 Non-cash lease expense 233 190 Net book value of consigned equipment sold 21 66 Loss on disposal of fixed assets 361 - Stock-based compensation 6,579 6,796 Credit loss (recovery) expense (130 ) 230 Change in excess/obsolete inventory reserve 137 - Amortization of discounts on investments (3,665 ) (3,641 ) Changes in operating assets and liabilities: Accounts receivable 1,327 3,990 Accounts receivable - TIA - 1,912 Inventory 833 (2,542 ) Prepaid expense and other current assets 1,322 724 Other assets (321 ) 212 Accounts payable, accrued expenses and other (3,497 ) (1,039 ) Operating lease liability (215 ) 112 Deferred revenue (1,701 ) (2,020 ) Other liabilities 27 (13 ) Net cash used in operating activities (15,398 ) (14,429 ) Cash flows from investing activities: Purchases of investments (79,353 ) (104,955 ) Maturities of investments 85,440 163,320 Purchases of property and equipment (1,098 ) (2,065 ) Proceeds from sale of equipment — 9 Net cash provided by investing activities 4,989 56,309 Cash flows from financing activities: Proceeds from exercise of stock options 1,151 1,613 Proceeds from issuance of common stock under employee stock purchase plan 265 - Net cash provided by financing activities 1,416 1,613 Net (decrease) increase in cash and cash equivalents (8,993 ) 43,493 Cash and cash equivalents, beginning of period 46,506 11,064 Cash and cash equivalents, end of period $ 37,513 $ 54,557 Unaudited Reconciliation of Net Loss to EBITDA
(in thousands)Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 (in thousands) Net loss $ (9,375 ) $ (10,512 ) $ (18,901 ) $ (21,394 ) Depreciation and amortization expense 1,081 1,026 2,192 1,988 Interest income (2,593 ) (2,561 ) (5,342 ) (4,857 ) Income taxes — — — — EBITDA $ (10,887 ) $ (12,047 ) $ (22,051 ) $ (24,263 ) %
